Illumina (Saul Checklist)

Hey,

Decided to take a look at illumina, please bear in mind this is the first time im doing anything like this, so i might be completely off base.

Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. These systems are enabling studies that were not even imaginable just a few years ago, and moving us closer to the realization of personalized medicine. With rapid advances in technology taking place, it is mission-critical to offer solutions that are not only innovative, but flexible, and scalable, with industry-leading support and service.

We strive to meet this challenge by placing a high value on collaborative interactions, rapid delivery of solutions, and meeting the needs of our customers.

Our customers include a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe.


Illumina			
			
Reccomendation	        No
		
	                Total	Product	Service
Revenue growth >35%:	31%	28%	44%
			
Special Niche:	        Yes, Gene tech		
			
Recurring Revenue:	Yes, Consumables		
			
High Gross Margin:	68.8% up from 61.5%		
			
Dropping losses as % of revenue:	Proffitable company		
			
Increasing Gross Margin:	Gross margin 68.8% up from 61.5%		
			
Increasing Proffits: 	Yes, Gross proffit up 46%		
			
Customer Aquisitions:	?		
			
Improving Cash Flow:	Yes, 59%		
			
Dropping OPEX as % of revenue:	Yes, OPEX remained relatively the same		
			
Dollar-Based retention rate obver 100%:	?		
			
High NPS:	No, Estimated at 14		
			
Founder Led:	No		
			
A lot of Cash and no debt:	No, 1560 Cash, 1180 Total liability mostly long term debt		
			
Low customer concentration (top three making up 40% of revenue):	customers include a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe.		

For me, it looks like a “Maybe” type of stock.

  • MK
14 Likes

I think this is Motley Fool recommended stock a year or so ago. ILMN if I recall.

My thesis for owning FMI was it was one of 2 companies I knew of that would be crucial in the selection of immunotherapies to best treat patients. FMI was unfortunately taken out (a nice premium) and that leaves ILMN as the sole stand alone company which would serve this purpose. It is not unknown and priced accordingly. I’d love to find another FMI if anyone knows of one.

Rob

I realize now that i have posted this incorrectly, as it does not show up us hypergrowth company, this is incorrect board. Let’s close the discussion and of anyone want’s you can move it elsewhere.

Thanks.

3 Likes